Ziqian Geng

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

Edward V. Loftus, Julián Panés, Ana P. Lacerda et al. · New England Journal of Medicine · 2023 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham et al. · JAMA Dermatology · 2020 · 216 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Falk G. Bechara, Maurizio Podda, Errol P. Prens et al. · JAMA Surgery · 2021 · 154 citations · Full text

Medicine, Pharmacotherapy, Surgery +8

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial

Boni E. Elewski, Martin M. Okun, Kim Papp et al. · Journal of the American Academy of Dermatology · 2017 · 84 citations · Full text

Medicine, Dermatology, Pharmacotherapy +12